跳至主要内容
临床试验/NCT02784184
NCT02784184Unknown不适用

COPENHAGEN Minipuberty Study

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 280 人开始时间: 2016年8月最近更新:
适应症

试验速览

阶段
不适用
入组人数
280
试验地点
1
主要终点
Serum and urinary metabolites of reproductive hormones (e.g. steroid hormone metabolites and gonadotropins) (newborn)

研究概览

简要总结

Minipuberty is a term used to describe the transient activation of the pituitary-gonadal axis 2-3 months after birth in both boys and girls. It is, however, not known why infants reach adult levels of reproductive hormones in early life, nor is the exact timing of the peak known. Furthermore, what determines the timing of peaks and suppressions of reproductive hormones from infancy throughout childhood and into adolescence remains to be elucidated.

The study aims to described and evaluate dynamic changes in the hypothalamic-pituitary- gonadal axis in early postnatal life.

详细描述

Minipuberty is a term used to describe the transient activation of the pituitary-gonadal axis 2-3 months after birth in both boys and girls. It is, however, not known why infants reach adult levels of reproductive hormones in early life, nor is the exact timing of the peak known. Furthermore, what determines the timing of peaks and suppressions of reproductive hormones from infancy throughout childhood and into adolescence remains to be elucidated.

Few studies have investigated minipuberty and one, for example, found that it is affected in premature infants (before gestation week 37). However, no studies on normative data throughout minipuberty in infants exist.

Furthermore, using minipuberty as a window for diagnosis of endocrine disorders and future reproductive function has been suggested. Defining minipuberty, both in terms of circulating hormone levels and urinary metabolites, in healthy infants is therefore essential in order to utilize this window. Studies using patients with Disorders of Sex Development during minipuberty have been carried out, but they are hampered by small sample sizes and lack of control groups.

In addition, little is known about the genetic and epigenetic factors that drive the onset, progression and termination of minipuberty as well as the actual puberty, i.e. the factors responsible for the quiescence of the HPG axis during childhood and the dis-inhibition responsible for pubertal onset. Therefore, much attention was drawn on the study performing whole exome sequencing in patients and relatives with central precocious puberty (CPP). For the first time, MKRN3 was suggested as the primary factor responsible for HPG inhibition during mid-childhood. A number of studies support that MKRN3 mutations cause CPP, and genetic variation of MKRN3 affect pubertal timing in healthy girls. Our findings of declining serum levels of MKRN3 prior to pubertal onset in healthy girls support MKRN3 as a regulator of pubertal onset. The exact mechanism through which MRKN3 exceeds its effect remains to be elucidated; however, its zink-finger structure indicates regulation of superior cellular processes such as epigenetic regulation of DNA transcription.

Twin studies suggest that 60% of the inter-individual variation is caused by genetic factors. However, genome wide association (GWA) studies only explain a fraction of the variation in age at puberty. Recently, our research group has revealed the largest effect of a single SNP on age at pubertal onset in girls. The location of the SNPs in genes regulating FSH action emphasizes the need of a wide focus including downstream processes in the HPG axis when evaluating factors regulating puberty.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 12 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Singleton pregnancy
  • Maternal and paternal Caucasian origin
  • Maternal pre-pregnancy BMI between 18 and 35 kg/m2
  • No serious maternal illness, including no pre-existing maternal diabetes nor thyroid gland diseases
  • Term pregnancy (week 37+0 to 41+7)
  • No gestational diabetes
  • No fetal malformations or chromosomal disorders
  • Birth weight of child between 3rd and 97th percentile
  • Only healthy infants born at term will be included in the study which all prospective participants will be informed of.

排除标准

  • 未提供

结局指标

主要结局

Serum and urinary metabolites of reproductive hormones (e.g. steroid hormone metabolites and gonadotropins) (newborn)

时间窗: 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth plus 40 days daily measurement (urine, female 40 days diaper study subgroup)

change/course serum and urinary metabolites

Basic clinical examination (newborn) (size and proportions)

时间窗: 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

change/course: measurements of length, weight, skin folds and hip-waist ratio

Basic clinical examination (newborn) (penile measurement)

时间窗: 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

change/course: penile measurement with a ruler (in boys)

Basic clinical examination (newborn) (AGD)

时间窗: 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

change/course: ano-genital distance (AGD) measured with a ruler

Urinary metabolites of endocrine disrupting chemicals (e.g. phthalates, phenols, perfluorinated compounds and parabens) (newborn)

时间窗: 3-7d, & 1,3,5,7,12m or 2,4,6,8,12m after birth plus 40 days daily measurement (urine, female 40 days diaper study subgroup)

change/course urinary metabolites

Basic clinical examination (newborn) (pubertal staging)

时间窗: 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

change/course: pubertal staging using Tanners classification (including testicular size in boys assessed by Prader's orchidometer and ultrasound

Epigenetic profiling

时间窗: single determination or 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

change/course: epigenetic variation of loci regulating hormone signalling

Basic clinical examination (newborn) (genitalia)

时间窗: 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

change/course: classification of external genitalia (classification of genital tubercle, location of gonads, position of urethra, labia/scrotal fusion)

Genetic profiling

时间窗: single determination or 3-7d, and 1,3,5,7,12m or 2,4,6,8,12m after birth

Genotyping of different genetic loci (genetic variation of loci regulating hormone signalling, e.g. FSHB, etc.)

次要结局

  • Basic clinical examination (parents) (height)(postpartal (within first 3 months))
  • Basic clinical examination (parents) (weight)(postpartal (within first 3 months))
  • Medical history and exposure (parents) (obstetrical)(postpartal (within first year))
  • Medical history and exposure (parents) (puberty)(postpartal (within first year))
  • Breastfeeding and food intake (newborn)(first year of life)
  • Medical history and exposure (parents) (basic)(postpartal (within first year))
  • Basic clinical examination (parents)(postpartal (within first 3 months))
  • Pregnancy and perinatal outcome (newborn and mother)(before birth and perinatal phase)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anders Juul

Anders Juul, MD, PhD, DmSc

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验